Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: GlobalData
$125.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Chugai Pharmaceutical Co Ltd's Anti-Cancer Agent "Avastin" Obtains Approval for Additional Indication and Dosage and Administration of Malignant Glioma-Yakuji Nippo


Friday, 14 Jun 2013 08:00pm EDT 

Yakuji Nippo reported that Chugai Pharmaceutical Co Ltd has obtained approval by the Japanese Ministry of Health, Labour and Welfare (MHLW) on June 14, 2013, for the additional indication and dosage and administration of "Malignant glioma" for the anti-cancer agent/anti-VEGF humanized monoclonal antibody, "AVASTIN I.V. Infusion 100mg/4mL and 400mg/16mL" (generic name: bevacizumab (recombinant) for Infusion). 

Company Quote

3855.0
-10.0 -0.26%
27 Mar 2015